Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

Merck and a woman suing the drugmaker agreed to halt a trial over alleged injuries from the drugmaker's human papillomavirus ...

Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new ...

(Reuters) -Merck and a woman suing the drugmaker agreed to halt a trial over alleged injuries from the drugmaker's human ...

Citi analyst Geoff Meacham maintained a Buy rating on Merck & Company (MRK – Research Report) today and set a price target of $115.00. The company’s shares closed yesterday at $90.74.

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Hold rating on Merck & Company (MRK – Research Report), with a price target of $110.00. The company’s shares closed ...

Merck’s earnings estimates for 2025-2030 were lowered, with 2030 EPS now forecast to be significantly below 2024 levels. TD Cowen cut its price target on Merck from $121 to $100, citing weaker ...

Merck on Tuesday issued full-year 2025 revenue guidance that fell short of Wall Street's expectations. The company said that sales range reflects a decision to halt shipments of Gardasil ...